

Yao Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3743143/publications.pdf>

Version: 2024-02-01

24
papers

383
citations

759233

12
h-index

794594

19
g-index

24
all docs

24
docs citations

24
times ranked

627
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. <i>JAMA Oncology</i> , 2022, 8, 364.	7.1	39
2	Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 20-30.	1.8	0
3	The head and neck cancer genome in the era of immunotherapy. <i>Oral Oncology</i> , 2021, 112, 105040.	1.5	13
4	Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. <i>Head and Neck</i> , 2021, 43, 1056-1062.	2.0	11
5	Any day, split halfway: Flexibility in scheduling high-dose cisplatin—A large retrospective review from a high-volume cancer center. <i>International Journal of Cancer</i> , 2021, 149, 139-148.	5.1	1
6	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1872-1884.	1.2	48
7	Reproducibility of radiomic features using network analysis and its application in Wasserstein k-means clustering. <i>Journal of Medical Imaging</i> , 2021, 8, 031904.	1.5	1
8	Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. <i>JAMA Network Open</i> , 2021, 4, e2113205.	5.9	34
9	TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. <i>JCO Precision Oncology</i> , 2021, 5, 1259-1269.	3.0	10
10	The effect of short radiation treatment breaks on chemoradiotherapy for oropharyngeal cancers. <i>Head and Neck</i> , 2021, 43, 3796-3809.	2.0	0
11	Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. <i>International Journal of Cancer</i> , 2020, 147, 107-115.	5.1	14
12	An imbalance in competing mortality favouring Debio 1143. <i>Lancet Oncology</i> , The, 2020, 21, e502.	10.7	2
13	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. <i>Oral Oncology</i> , 2020, 104, 104641.	1.5	16
14	The 3 Bs of cancer care amid the COVID-19 pandemic crisis: “Be safe, be smart, be kind” A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. <i>Cancer</i> , 2020, 126, 4092-4104.	4.1	24
15	Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 110, 104877.	1.5	22
16	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.	1.8	24
17	Complex chest wall surgery to prevent vascular complications after immunotherapy and radiation treatment. <i>JTCVS Techniques</i> , 2020, 4, 329-331.	0.4	2
18	Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. <i>Head and Neck</i> , 2019, 41, 3551-3563.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Organ preservation for patients with anterior mucosal squamous cell carcinoma of the nasal cavity: Rhinectomyâ€free survival in those refusing surgery. <i>Head and Neck</i> , 2019, 41, 2741-2747.	2.0	11
20	IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi121-vi121.	1.2	0
21	JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. <i>Future Oncology</i> , 2019, 15, 687-694.	2.4	41
22	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 130-142.	1.7	40
23	Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). <i>International Journal of Particle Therapy</i> , 2019, 5, 1-10.	1.8	10
24	Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 0, , .	7.1	4